Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SANOFI

SANOFI

Sanofi India Limited
Micro-capPharma ↗

What the six lenses say about SANOFI — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹3122.0
2026-09-08
VWAP · 1Y anchor
₹3741
-16.5% from VWAP
P/E · TTM
17.4×
TTM EPS ₹179.4
52-week range
1%
position low→high
RSI(14)
36
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How SANOFI’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD23›

The actual numbers

Price vs VWAP (1y)-16.5%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-16.7%
Price vs 50-EMA-4.8%
RSI(14)36
RS vs Nifty 500 · 3M-5.7%
RS vs sector · 3M-11.8%
52-week range1%
Volume vs 30d avg0.48×
Volume vs 60d avg0.51×
ATR(14) · volatility72.3
Bollinger width · vol contraction0.086
FundamentalD644›

The actual numbers

Return on equity (ROE)48.0%
Operating margin23.1%
Net margin18.5%
Revenue growth · YoY-21.6%
EPS growth · YoY-31.5%
Debt / equity0.02×

Full 8-quarter history in the financials table below.

ValuationD966›

The actual numbers

P/E (TTM)17.4×
TTM EPS₹179.4
52-week range1%
CatalystD330›

The actual numbers

Earnings & momentum22
Capital actions13
Governance91

Every filing in the corporate-announcements panel below.

FlowD858›

The actual numbers

Promoter holding60.4%
Delivery · 30d avg62.3%
Up/down-day asymmetry-0.9pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D2 + D8 ) ÷ 2 = 5.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
8
Conviction score 8/100 · avg-decile strength 5.0/10
Conviction score8/100›
TechnicalD2›
FundamentalD6›
ValuationD9›
CatalystD3›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.7pp
+1.2pp
-3.4pp
-4.1pp
-14.7pp
-34.5pp
Nifty 500
Broad-market baseline
-0.7pp
+1.2pp
-4.5pp
-5.7pp
-20.5pp
-39.8pp
Sector
Own-sector index
—
—
-7.3pp
-11.8pp
-33.6pp
-60.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SANOFI daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
3122.00-36.20

Relative strength

RS vs baseline · rebased to 100

SANOFI ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
43.27-0.32

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24
Revenue (₹cr)706715694732464524515
↳ change QoQ—+1.2%-2.9%+5.5%-36.7%+13.1%-1.7%
EBITDA (₹cr)194220199199102122132
EBITDA margin27.5%30.8%28.7%27.1%21.9%23.3%25.7%
PAT (₹cr)1231521381371038291
↳ change QoQ—+23.6%-9.4%-0.8%-24.5%-20.4%+11.1%
Net margin17.4%21.3%19.8%18.6%22.3%15.7%17.7%
EPS (₹)53.3765.9559.7959.3144.8135.6939.64
D/E———————
YoY growth · Dec '24Revenue -25.8% YoYPAT -33.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    LOWgovernance
    Action(s) taken or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds SANOFI

Mutual funds holding SANOFI (4)

FundWeightAUM ₹crGrade
Nippon India Pharma Bns1.07%9,279
Nippon India Pharma Gr1.07%9,279
Abakkus Small Cap Reg Gr1.40%2,113
Bandhan Healthcare Reg Gr1.45%319

ETFs holding SANOFI (0)

No tracked ETF holds SANOFI ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma